홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Estazolam

HCID 3261
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
29975-16-4
표준 SMILES
Clc1ccc2c(c1)C(c1ccccc1)=NCc1nncn1-2
InChIKey
CDCHDCWJMGXXRH-UHFFFAOYSA-N
분자식
C16H11ClN4
평균 분자량
294.74 g/mol
단동위원소 질량
294.0672241

개요

Estazolam is a triazolo[4,3-a][1,4]benzodiazepine having a phenyl group at position 6 and a chloro substituent at position 8. A short-acting benzodiazepine with general properties similar to diazepam, it is given by mouth as a hypnotic in the short-term management of insomnia. It has a role as an anxiolytic drug, an anticonvulsant and a GABA modulator. It is a triazolobenzodiazepine and a member of triazoles.

이름 및 식별자

우선 이름
Estazolam
IUPAC
8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
영어명
Estazolam
분자식
C16H11ClN4
분자량
294.74

이름 및 동의어

estazolam29975-16-4EurodinProSomEsilganD 40TAEstazolamum8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepineAbbott-47631Estazolam civDTXSID50205728-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine
이름 더 보기
8-CHLORO-6-PHENYL-4H-[1,2,4]-TRIAZOLO[4,3-A][1,4]BENZODIAZEPINEu33737Cannocd-40taNemurelJulodin
NSC-29081836S3EQV54C4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-phenyl-8-Chloro-6-phenyl-4H-(1,2,4)triazolo-(4,3-a)(1,4)benzodiazepineDTXCID50572CHEBI:48588-Chloro-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepineNSC290818

데이터베이스 식별자

CAS
29975-16-4
PubChem CID
3261
DTXSID
DTXSID5020572
ChEMBL
CHEMBL285674
ChEBI
CHEBI:4858
UNII
36S3EQV54C
EC Number

물성

구조 계산 물성보충 중

XLogP
1.7
극성 표면적
43.1 Ų
수소 결합 공여자 수
0
수소 결합 수용자 수
3
회전 가능 결합 수
1
무거운 원자 수
21
형식 전하
0
복잡도
407

실험 및 물리화학적 성질

Drugs · 5건

DEA NFLIS-Drug Category -> Benzodiazepines

DEA Schedule IV Controlled Substance -> Depressants

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Benzodiazepines

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

LogP4.7
Solubility · 2건

Practically insoluble (1.5 mg/L)

4.23e-02 g/L

Human Drugs · 4건

Breast Feeding; Lactation; Milk, Human; Benzodiazepines; Hypnotics and Sedatives

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Melting Point · 2건

228-229

228.5 °C

Physical DescriptionSolid
Collision Cross Section168.1 Ų [M+H]+ [CCS Type: DT; Method: single field calibrated]

물리화학적 성질

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 5건

This chemical does not meet GHS hazard criteria for 2.3% (1 of 44) of reports.

Warning

H315 (93.2%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 44 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Regulatory Information · 2건

DEA schedule IV controlled substance

4H-1,2,4Triazolo4,3-a1,4benzodiazepine, 8-chloro-6-phenyl-: Does not have an individual approval but may be used under an appropriate group standard

Hazard Classes and CategoriesSkin Irrit. 2 (93.2%)

독성 정보

Treatment · 1건

Gastric evacuation, either by the induction of emesis, lavage, or both, should be performed immediately. Maintenance of adequate ventilation is essential. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated. Fluids should be administered intravenously to maintain blood pressure and encourage diuresis. The value of dialysis in treatment of benzodiazepine overdose has not been determined. The physician may wish to consider contacting a Poison Control Center for up-to-date information on the management of hypnotic drug product overdose. Flumazenil, a specific benzodiazepine receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be used in situations when an overdose with a benzodiazepine is known or suspected. (L1712)

화학 및 산업

약리 정보

ATC Code · 2건

N - Nervous system

QN - Nervous system

Protein Binding93% protein bound, independant of concentration.
PharmacodynamicsEstazolam, a triazolobenzodiazepine derivative, is an oral hypnotic agent with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam.
Mechanism of Action · 1건

Benzodiazepines bind nonspecifically to benzodiazepine receptors, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABA<sub>A</sub>) receptors, this enhances the effects GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.

Biological Half-LifeThe range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.
Metabolism/Metabolites · 3건

Extensively metabolized in the liver. In vitro studies with human liver microsomes indicate that the biotransformation of estazolam to the major circulating metabolite 4-hydroxy-estazolam is mediated by cytochrome P450 3A (CYP3A).

Estazolam has known human metabolites that include 4-hydroxyestazolam.

Extensively metabolized in the liver. In vitro studies with human liver microsomes indicate that the biotransformation of estazolam to the major circulating metabolite 4-hydroxy-estazolam is mediated by cytochrome P450 3A (CYP3A). Route of Elimination: Estazolam is extensively metabolized. The elimination of the parent drug takes place via hepatic metabolism of estazolam to hydroxylated and other metabolites that are eliminated largely in the urine both free and conjugated. Less than 5% of a 2 mg dose of estazolam was excreted unchanged in the urine, with only 4% of the dose appearing in the feces. Radiolabel mass balance studies indicate that the main route of excretion is via the kidneys. After 5 days, 87% of the administered radioactivity was excreted in human urine. Less than 4% of the dose was excreted unchanged. Half Life: The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.

관련 반응

7건
반응 기록 만들기
HRID 615852 반응식
HRID 615852반응물로
HRID 615853 반응식
HRID 615853반응물로
HRID 867066 반응식
HRID 867066생성물로
HRID 1288066 반응식
HRID 1288066생성물로
HRID 1764511 반응식
HRID 1764511생성물로
HRID 1764512 반응식
HRID 1764512생성물로
HRID 1764513 반응식
HRID 1764513생성물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
249-982-4
Nikkaji
J9.280K
녹는점
228 · 228-229°
끓는 점
448.04 °C · 448.04°C (rough estimate)
밀도
1.2294 · 1.2294 (rough estimate)
굴절률
1.611 · 1.6110 (estimate)
인화점
11 °C · 11 °C
저장 조건
2 · 2-8°C
용해도
30 mg/ml; · DMF: 30 mg/ml; DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml; DMSO: 20 mg/ml; Ethanol: 10 mg/ml
물리적 상태
결정성 고체
산도 계수 (pKa)
2.84 · pKa 2.84(H2O) (Uncertain)
NIST
Estazolam(29975-16-4)
Health Effects
May cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease.
Hepatotoxicity · 1건

Estazolam, as with other benzodiazepines, is rarely associated with serum ALT elevations, and clinically apparent liver injury from estazolam is extremely rare, if it occurs at all. There have been no published case reports of symptomatic, acute liver injury from estazolam. Isolated cases of clinically apparent hepatitis have been reported with other benzodiazepines including alprazolam, chlordiazepoxide, clonazepam, diazepam, flurazepam, lorazepam, and triazolam. The clinical pattern of acute liver injury from benzodiazepines is typically cholestatic and mild-to-moderate in severity with a latency of 1 to 6 months and full recovery within 1 to 2 months. Fever and rash have not been described nor has autoantibody formation.

Exposure Routes · 1건

Tablets have been found to be equivalent in absorption to an orally administered solution of estazolam. In healthy subjects who received up to three times the recommended dose, peak estazolam plasma concentrations occurred within two hours after dosing (range 0.5 to 6.0 hours) and were proportional to the administered dose, suggesting linear pharmacokinetics over the dosage range tested.

Toxicity Summary · 1건

Benzodiazepines bind nonspecifically to benzodiazepine receptors, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABA<sub>A</sub>) receptors, this enhances the effects GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.

Signs and SymptomsSymptoms of overdose include confusion, depressed breathing, drowsiness and eventually coma, lack of coordination, and slurred speech.
Carcinogen Classification · 6건

Estazolam

Group 3: Not classifiable as to its carcinogenicity to humans

Volume 66: (1996) Some Pharmaceutical Drugs

1996

1996

3, not classifiable as to its carcinogenicity to humans. (L135)

Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Estazolam

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation · 2건

◉ Summary of Use during Lactation

◈ What is estazolam?

Toxicity DataLD50: 740 mg/kg (oral, male mice) (L1867) LD50: 3200 mg/kg (oral, rat) (L1867) LD50 300 mg/kg (oral, rabbit) (L1867)

안전 데이터

wgk
3
rtecs
XZ5473500
ridadr
3249
독성
LD50 orally in male mice, rats and rabbits: 740, 3200, 300 mg/kg (Yokotani)
HS 번호
2933910000
risk_code
36/37/38-39/23/24/25-23/24/25-11
hazard_code
Xi,T,F
safety_code
36/37/39-45-36/37-16-7
포장분류
III
위험 등급
6.1(b)
기존화학 물질
KE-05865
FDA Pharmacological Classification · 6건

36S3EQV54C

ESTAZOLAM

Established Pharmacologic Class [EPC] - Benzodiazepine

Chemical Structure [CS] - Benzodiazepines

Estazolam is a Benzodiazepine.

ESTAZOLAM

MeSH Pharmacological Classification · 3건

Drugs used to prevent SEIZURES or reduce their severity.

Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.

Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here.

Absorption, Distribution and Excretion · 2건

Tablets have been found to be equivalent in absorption to an orally administered solution of estazolam. In healthy subjects who received up to three times the recommended dose, peak estazolam plasma concentrations occurred within two hours after dosing (range 0.5 to 6.0 hours) and were proportional to the administered dose, suggesting linear pharmacokinetics over the dosage range tested.

Estazolam is extensively metabolized. The elimination of the parent drug takes place via hepatic metabolism of estazolam to hydroxylated and other metabolites that are eliminated largely in the urine both free and conjugated. Less than 5% of a 2 mg dose of estazolam was excreted unchanged in the urine, with only 4% of the dose appearing in the feces. Radiolabel mass balance studies indicate that the main route of excretion is via the kidneys. After 5 days, 87% of the administered radioactivity was excreted in human urine. Less than 4% of the dose was excreted unchanged.

Tissue LocationsKidney
Cellular LocationsMembrane

용도 및 제조

UsesFor the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.
Use ClassificationPharmaceuticals

응용 분야

용도A benzodiazepine derivative possessing anxiolytic, anticonvulsant, and muscle relaxant properties. It is commonly prescribed to treat short-term insomnia. Controlled Substance.

상·하류 제품 정보

상류 원료

P-클로로니트로벤젠phenylacetonitrile오소포름산에틸클로로아세틸 클로라이드헥사민Formylhydrazine2-(2-Acetylhydrazino)-7-chloro-5-phenyl-3H-1,4-benzodiazepineN-데스메틸-N(4)-데스옥시클로르디아제폭시드포르마미딘 하이드로클로라이드
추가 설명 · 1건

정의ChEBI: A triazolo[4,3-a][1,4]benzodiazepine having a phenyl group at position 6 and a chloro substituent at position 8. A short-acting benzodiazepine with general properties similar to diazepam, it is given by mouth as a hypnotic in the short-term ma agement of insomnia.